REVB

Revelation BiosciencesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$1.40

Analysis reference price unavailable

Analysis 2026-05-09 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$0.85

Analysis reference price unavailable

Analysis 2026-05-09 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.45

Analysis reference price unavailable

Analysis 2026-05-09 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-09

AI commentary

The post-earnings setup is still tentative because coverage is thin and no trustworthy post-print analyst target or rating revision was available in the packet. With a $1.02 anchor on May 7, 2026 and a negative deterministic prior, the May 7 filing is best treated as a monitoring update around runway, going-concern language, and AKI execution rather than a confirmed thesis turn.

RankAlpha Sentiment Codex - 2026-05-09

Open post-earnings memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-08-31catalystPost-earnings cash update reduced immediate liquidity pressure but did not remove financing riskHigh impact

The May 7 8-K confirms Revelation furnished Q1 2026 financial results, and the Q1 10-Q remains the controlling primary-source risk marker: current cash was still described as insufficient to sustain operations for one year from issuance, with substantial doubt about going concern. The earnings follow-up therefore remains financing-sensitive rather than a clean liquidity reset [#8-K-2026-05-07] [#10-Q-2026-05-07].

2026-09-30eventGEM-AKI Phase 2/3 study-start progress remains the main upside checkpointHigh impact

The prior baseline and 2025 10-K support that management planned during 2026 to build study infrastructure, engage a CRO, manufacture blinded drug and placebo, and move toward starting the GEM-AKI adaptive Phase 2/3 study as feasible. Until Revelation confirms trial initiation or enrollment, this remains a monitoring catalyst rather than a proven rerating event [#10-K-2026-02-26] [#8-K-2026-05-07].

2026-12-31catalystGEM-CKD toxicology and repeat-dose preparation remain secondary pipeline proof pointsHigh impact

The 2025 10-K says Revelation intends during 2026 to conduct preclinical toxicology studies to support a repeat-dose Phase 2 CKD study. That could help validate broader Gemini platform optionality, but it is earlier stage and lower visibility than GEM-AKI study-start progress [#10-K-2026-02-26].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-09 • Updated nightlySource: Internal modelMethodology